Table SI. Characteristics of patients with RRMS.

Patient	Age	Sex	EDSS	Treatment
Patient 1	29	Male	4.5	Untreated
Patient 2	50	Female	6	Untreated
Patient 3	33	Female	6	Untreated
Patient 4	35	Female	6	Fingolimod
Patient 5	36	Female	6	Fingolimod
Patient 6	40	Male	5.5	Fingolimod
Patient 7	47	Female	3.5	Fingolimod
Patient 8	48	Female	2.5	Fingolimod
Patient 9	42	Male	3.5	Fingolimod
Patient 10	35	Female	3	Fingolimod
Patient 11	23	Male	6	IFN β -1b
Patient 12	45	Female	1	IFN β -1b
Patient 13	36	Male	3.5	IFN β -1b
Patient 14	34	Male	2	IFN β -1b
Patient 15	40	Female	1	IFN β -1b
Patient 16	55	Female	2	IFN β -1b
Patient 17	45	Male	5.5	IFN β -1a
Patient 18	55	Male	3	IFN β -1a
Patient 19	29	Female	3	IFN β -1a
Patient 20	34	Female	1	IFN β -1a
Patient 21	49	Female	2	IFN β -1a
Patient 22	46	Female	1.5	IFN β -1a
Patient 23	30	Female	2	Fingolimod
Patient 24	28	Female	1	Fingolimod
Patient 25	34	Female	2	Fingolimod

Table SII.Characteristics of healthy controls.

Subject	Age	Sex
Control 1	26	Male
Control 2	50	Female
Control 3	33	Female
Control 4	26	Female
Control 5	27	Female
Control 6	24	Male
Control 7	24	Female
Control 8	30	Female
Control 9	28	Male
Control 10	35	Female

Table SIII. Results of target prediction analysis between miR-155 and genes of interest using bioinformatics analysis.

miRNA	Target mRNA	Software	Number of hits	Start	End	Energy
miR-155	ICAM1	PITA	1	2062	2054	-15.7
	ITGB2	Targetspy	1	2710	2741	-10.83
	Perforin	PITA	1	2024	2016	-8.7
	Granzyme B	PITA	1	600	592	-15.6
miR or miRNA, microRNA; ICAM1, intracellular adhesion molecule-1; ITGB2, integrin subunitβ2; PITA, Probability of Interaction by Target Accessibility.						